**AstraZeneca Response – 18 September 2014**

**Empagliflozin combination therapy for treating type 2 diabetes [ID641]**

**Appraisal Consultation Document**

Thank you for the opportunity to comment on the above Appraisal Consultation Document (ACD). Our comments are provided below in response to the specific consultation questions.

- **Has all of the relevant evidence been taken into account?**

Whilst we agree that all the clinical trial evidence for empagliflozin has been taken into account, we also agree with the ERG's and Appraisal Committees concerns regarding the network meta-analyses and economic model submitted by the company and the need for further information.

- **Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?**

Whilst the current summaries reflect the evidence presented we anticipate that following consideration of the requested validated economic model, the corrected network meta-analyses and the requested sensitivity analyses these will be subject to change.

- **Are the provisional recommendations sound and a suitable basis for guidance to the NHS?**

Not applicable.

We have assumed that with new information being submitted a further Appraisal Consultation Document will be issued and we welcome the opportunity to comment on any provisional recommendations issued following the next meeting of the Appraisal Committee.